Larvol Delta - Carisma-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Study-of-CT0508-in-Combination-with-KEYTRUDA-pembrolizumab-in-Patients-with-HER2-Overexpressing-Solid-Tumors

CT-0508 - CARISMA Therap

https://www.prnewswire.com/news-releases/carisma-therapeutics-announces-first-patient-dosed-in-phase-1-study-of-ct-0508-in-combination-with-keytruda-pembrolizumab-in-patients-with-her2-overexpressing-solid-tumors-301865175.html

Jun 28, 2023

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next